Page 1 | Search Results | Blood | American Society of Hematology

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Patient-Reported Quality of Life before and after Stopping Treatment in the ENESTop Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase

Blood (2016) 128 (22): 1891.

https://doi.org/10.1182/blood.V128.22.1891.1891

Published: 2016

Journal Articles

Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase According to Reasons for Switching from Imatinib to Nilotinib: Subgroup Analysis from ENESTop

Timothy P. Hughes, MD FRACP, FRCPA, MBBS, FAAHMS, Carla Maria Boquimpani, Naoto Takahashi, MD PhD, Noam Benyamini, MD, Nelma Cristina D Clementino, MD, Vasily Shuvaev, MD, Sikander Ailawadhi, MD, Jeffrey H. Lipton, MD PhD, Anna G Turkina, Prof., MD, Elena Beatriz Moiraghi, MD, Franck E. Nicolini, MD PhD, Jolanta Dengler, Tomasz Sacha, Dong-Wook Kim, MD PhD, Rafik Fellague-Chebra, MD MSc, Sandip Acharya, MSc, Nancy Krunic, PhD, Yu Jin, MS, François-Xavier Mahon, MD PhD

Blood (2016) 128 (22): 792.

https://doi.org/10.1182/blood.V128.22.792.792

Published: 2016

Journal Articles

Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib

Timothy P. Hughes, Jeffrey H. Lipton, Nelson Spector, Francisco Cervantes, Ricardo Pasquini, Nelma Cristina D. Clementino, Pedro Enrique Dorlhiac Llacer, Anthony P. Schwarer, Francois-Xavier Mahon, Delphine Rea, Susan Branford, Das Purkayastha, LaTonya Collins, Tomasz Szczudlo, Brian Leber

Blood (2014) 124 (5): 729–736.

https://doi.org/10.1182/blood-2013-12-544015

Published: 2014

Journal Articles

]Socioeconomic Factors May Select Adults Younger Than 60 Years of Age with “De Novo” Acute Myeloid Leukemia To Receive Intensive Treatment outside a Clinical Trial in Developing Countries. Experience of a Brazilian University Center.

Evandro M. Fagundes, MD, Vanderson Rocha, MD, Ana Beatriz F. Glória, MD, Nelma Cristina D. Clementino, MD, José S. Quintão, MD, Joao Paulo O. Guimaraes, MD, Enio Roberto P. Pedroso, MD, Marcos B. Viana, MD

Blood (2004) 104 (11): 4517.

https://doi.org/10.1182/blood.V104.11.4517.4517

Published: 2004

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Patient-Reported Quality of Life before and after Stopping Treatment in the ENESTop Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase

Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase According to Reasons for Switching from Imatinib to Nilotinib: Subgroup Analysis from ENESTop

Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib

]Socioeconomic Factors May Select Adults Younger Than 60 Years of Age with “De Novo” Acute Myeloid Leukemia To Receive Intensive Treatment outside a Clinical Trial in Developing Countries. Experience of a Brazilian University Center.

Email alerts

ASH Publications

American Society of Hematology

Update search

Patient-Reported Quality of Life before and after Stopping Treatment in the ENESTop Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase

Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase According to Reasons for Switching from Imatinib to Nilotinib: Subgroup Analysis from ENESTop

Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib

]Socioeconomic Factors May Select Adults Younger Than 60 Years of Age with “De Novo” Acute Myeloid Leukemia To Receive Intensive Treatment outside a Clinical Trial in Developing Countries. Experience of a Brazilian University Center.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only